We initiate coverage on Basilea, a commercial-stage Swiss biotech company focused on treatment-resistant infections and cancers, with an OUTPERFORM recommendation and target price of CHF107/share, which is c.60% above the share price. Basilea recently completed a busy period during which it signed commercialisation agreements with global and regional leaders for its two marketed hospital anti-infectives, antifungal Cresemba (isavuconazole) and MRSA antibiotic Zevtera (ceftobiprole), in most k
19 Mar 2018
Reaping the rewards of an intense BD period
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Reaping the rewards of an intense BD period
Basilea Pharmaceutica AG (0QNA:LON) | 4,620 0 0.0% | Mkt Cap: 605.3m
- Published:
19 Mar 2018 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
44
We initiate coverage on Basilea, a commercial-stage Swiss biotech company focused on treatment-resistant infections and cancers, with an OUTPERFORM recommendation and target price of CHF107/share, which is c.60% above the share price. Basilea recently completed a busy period during which it signed commercialisation agreements with global and regional leaders for its two marketed hospital anti-infectives, antifungal Cresemba (isavuconazole) and MRSA antibiotic Zevtera (ceftobiprole), in most k